Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PTCT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPTC wins bankruptcy auction for BLA-stage Fabry gene therapy ST-920 for $111M upfront
Filed August 13, 2026 · Period ending August 12, 2026 · ~1 min read
Key Changes
-
high
PTC selected as winning bidder to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics bankruptcy for $111M upfront plus up to $100M in FDA approval milestones ($80M accelerated, $20M full approval).
Item 8.01 verify on EDGAR → -
high
Rolling BLA submission for accelerated approval expected to complete Q4 2026 based on 52-week Phase 1/2 STAAR study showing positive mean annualized eGFR slope, differentiated from other Fabry therapies that showed negative eGFR slope despite improved renal function.
Item 8.01 verify on EDGAR → -
high
Acquisition targets estimated 11,000 U.S. Fabry patients with one-time gene therapy designed to enable long-term enzyme production; transaction subject to bankruptcy court approval, antitrust review, and definitive documentation, expected to close late Q3 or early Q4 2026.
Item 8.01 verify on EDGAR → -
medium
Management states acquisition will not impact company's objective of reaching cashflow break even in 2026; leverages existing rare disease commercial infrastructure without requiring new development or commercial build-out.
Exhibit 99.1 view on EDGAR →
Summary
PTC Therapeutics won a competitive bankruptcy auction to acquire ST-920, a late-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics. The company will pay $111 million upfront and up to $100 million in milestone payments tied to FDA approvals.
ST-920 is already at the BLA submission stage, with the rolling submission expected to complete in Q4 2026 based on 52-week Phase 1/2 STAAR study data showing positive mean annualized eGFR slope—a differentiated result compared to other Fabry therapies that showed improved renal function but still negative eGFR slope from baseline.
For PTC shareholders, this acquisition adds a potentially near-term commercial asset targeting an estimated 11,000 U.S. Fabry patients without requiring new commercial infrastructure build-out. The transaction remains subject to bankruptcy court approval, antitrust review, and definitive documentation, with closing expected late Q3 or early Q4 2026. Management stated the acquisition will not impact the company's 2026 cashflow break-even objective. The milestone structure aligns payment to regulatory success, with the bulk ($80M) tied to accelerated approval and $20M to full approval. If the BLA submission completes on schedule in Q4 2026, commercial launch could occur in 2027.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the Company was selected as the winning bidder to acquire ST-920, a BLA-stage one-time administered AAV gene therapy product candidate for Fabry disease, from Sangamo Therapeutics, Inc. (“Sangamo”), in a competitive bankruptcy auction conducted in connection with the Chapter 11 bankruptcy case of Sangamo
PTC Therapeutics was selected as the winning bidder in a competitive bankruptcy auction to acquire ST-920 from Sangamo Therapeutics. ST-920 is a BLA-stage (Biologics License Application stage) one-time administered AAV gene therapy product candidate for Fabry disease, meaning it is in late-stage development and has been submitted or is ready for submission to the FDA for approval. The acquisition occurred through Sangamo's Chapter 11 bankruptcy proceedings.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Acquisition remains subject to finalization of definitive documentation, bankruptcy court approval, antitrust review, and the satisfaction of other customary closing conditions. The Acquisition is expected to close late in the third quarter or early in the fourth quarter of 2026.
The acquisition requires bankruptcy court approval, antitrust clearance, and definitive documentation before closing. The bankruptcy court requirement indicates the target is in bankruptcy proceedings. Closing is targeted for late Q3 or early Q4 2026.
Added in current filing · verify on EDGAR →
A rolling biologics license application (“BLA”) submission to FDA for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026. The BLA is based on the evidence of meaningful favorable clinical effect on renal function and safety and tolerability profile over 52 weeks in the Phase 1/2 STAAR study of ST-920.
PTC plans to complete a rolling BLA submission for ST-920 seeking accelerated approval in Q4 2026. The application is based on 52-week Phase 1/2 STAAR study data showing favorable effects on renal function and safety. The company also expects to pursue regulatory approval outside the United States.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026. The BLA is based on evidence of meaningful favorable clinical effect on renal function and safety and tolerability profile over 52 weeks in the Phase 1/2 STAAR study.
The BLA submission for accelerated approval is expected to be completed in Q4 2026, with potential for commercial launch in 2027. The submission is based on 52-week data from the Phase 1/2 STAAR study showing favorable effects on renal function. The nonclinical and clinical BLA modules have already been submitted as part of a rolling submission, with only the CMC package remaining.
Added in current filing · view on EDGAR →
The Phase 1/2 STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks following ST-920 administration, as well as evidence of favorable effect on other aspects of Fabry disease including cardiac function and quality of life. The finding of improved eGFR over 52 weeks is differentiated from other Fabry therapies which demonstrated improved renal function but still negative eGFR slope from baseline.
The STAAR study showed positive mean annualized eGFR slope at 52 weeks, which PTC characterizes as differentiated from other Fabry therapies that showed improved renal function but still negative eGFR slope. The therapy also showed favorable effects on cardiac function and quality of life. Durability has been demonstrated with sustained α-Gal A activity maintained for up to 4.5 years in the earliest treated participant.
Added in current filing · view on EDGAR →
It is estimated that there are 11,000 people living with Fabry disease in the United States with similar prevalence rates in markets where PTC has the potential to commercialize.
The addressable market includes an estimated 11,000 people with Fabry disease in the United States, with similar prevalence in other markets where PTC can commercialize. ST-920 is designed as a one-time administered gene therapy that enables long-term enzyme production and significant reduction in disease markers, potentially reducing the burden of chronic enzyme replacement therapy.
Added in current filing · view on EDGAR →
The acquisition remains subject to definitive documentation, bankruptcy court approval, antitrust review, and other customary closing conditions. It is expected to close in late Q3 or early Q4 2026.
The acquisition is not yet final and requires definitive documentation, bankruptcy court approval, antitrust review, and other customary closing conditions. The transaction is expected to close in late Q3 or early Q4 2026. Management stated the acquisition will not impact the company's objective of reaching cashflow break even in 2026.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 14, 2026 · How we verify